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ABSTRACT
For the past 15–20 years, the intracellular delivery
and silencing activity of oligodeoxynucleotides
have been essentially completely dependent on the
use of a delivery technology (e.g. lipofection).
We have developed a method (called ‘gymnosis’)
that does not require the use of any transfection
reagent or any additives to serum whatsoever, but
rather takes advantage of the normal growth
properties of cells in tissue culture in order to
promote productive oligonucleotide uptake. This
robust method permits the sequence-specific
silencing of multiple targets in a large number of
cell types in tissue culture, both at the protein and
mRNA level, at concentrations in the low
micromolar range. Optimum results were obtained
with locked nucleic acid (LNA) phosphorothioate
gap-mers. By appropriate manipulation of oligo-
nucleotide dosing, this silencing can be con-
tinuously maintained with little or no toxicity for
>240 days. High levels of oligonucleotide in the
cell nucleus are not a requirement for gene
silencing, contrary to long accepted dogma. In
addition, gymnotic delivery can efficiently deliver
oligonucleotides to suspension cells that are
known to be very difficult to transfect. Finally, the
pattern of gene silencing of in vitro gymnotically
delivered oligonucleotides correlates particularly
well with in vivo silencing. The establishment of
this link is of particular significance to those in the
academic research and drug discovery and develop-
ment communities.
INTRODUCTION
It has long been believed that oligodeoxynucleotides, in
the absence of a transfection method such as lipofection,
cannot be eﬃciently used as silencing molecules for in vitro
studies. This notion was accepted because oligonucleotide
polarity renders them impermeable to hydrophobic cell
membranes (1). Further, the observation by microscopy
of bright nuclear staining after cellular microinjection or
lipo-transfection with ﬂuorescent oligonucleotides has
been considered the sine qua non for RNAse H-mediated
gene silencing (2–6). Thus, the screening of libraries of
sequence-complementary oligomers produced by ‘mRNA
walking’ for optimally active molecules has virtually
always relied on carrier-dependent cellular transfection.
This contrasts with the in vivo situation, where
oligonucleotide silencing has traditionally not depended
on carrier-dependent transfection.
We have developed a process (called ‘gymnosis’) that
does not require the use of any transfection reagent or
any additives to serum whatsoever, but rather takes
advantage of the normal growth properties of cells in
tissue culture in order to promote productive oligo-
nucleotide uptake. This robust method permits the
sequence-speciﬁc silencing of multiple targets in a large
number of cell types in tissue culture, both at the
protein and mRNA level, at concentrations in the low
micromolar range. Optimum results were obtained with
locked nucleic acid (LNA) phosphorothioate gap-mers.
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Cells
The 518A2 mycoplasma-free human melanoma cell
line was a kind gift of Dr Volker Wachek (University
of Vienna, Austria). Cells were grown in DMEM
(Invitrogen, Grand Island, NY, USA) supplemented
with 10% heat-inactivated fetal bovine serum, 2mM
L-glutamine, and 100U/ml penicillin G sodium and
100mg/ml streptomycin sulfate. Melanoma cells (591.8,
1000 and 1000.36) were isolated from patients with
advanced melanomas by Dr J. Kirkwood (University of
Pittsburgh, PA, USA), expanded and frozen. These lines
were grown in RPMI (Invitrogen) supplemented as above
with the inclusion of 1% MEM. HT-1080 ﬁbrosarcoma
and Namalwa Burkitt’s lymphoma cells were obtained
from the American Type Culture Collection (ATCC,
Rockville, MD, USA), and were grown in MEM supple-
mented with 10% fetal bovine serum and 100U/ml
penicillin G sodium and 100mg/ml streptomycin sulfate.
Huh-7 human hepatoma cells were grown in DMEM
(Sigma, St Louis, MO, USA). Both media were supple-
mented with 10% heat-inactivated fetal bovine serum,
2mM Glutamax, (Invitrogen), 25mg/ml gentamicin and
1  nonessential amino acids (Sigma). Stock cultures of
all cell lines were maintained at 37 C in a humidiﬁed
5% CO2 incubator.
Materials
The anti-Bcl-2 monoclonal antibody was purchased
from Dako (Carpinteria, CA, USA). The anti-a-tubulin
monoclonal antibody was from Sigma. The anti-poly
(ADP-ribosyl)polymerase (PARP) monoclonal, anti-pro-
caspase-3 monoclonal, anti-Bcl-xL polyclonal, anti-Mcl-1
polyclonal antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA, USA). The anti-PKC-a
monoclonal antibody was purchased from Neo
Transduction Laboratories (Lexington, KY, USA). The
antisurvivin polyclonal antibody was purchased from
Novus Biological (Littleton, CO, USA). Fetal bovine
serum was purchased from Invitrogen. A list of the
oligomers employed is presented in Table 1.
Gymnotic delivery of oligonucleotides
Adherent cells were seeded at low plating density in
complete media containing 10% fetal bovine serum (FBS)
the day before the experiment in 6-well plates, so that they
would just attain conﬂuence on the ﬁnal day of the exper-
iment. The day after plating, oligonucleotides dissolved
in PBS were added and mixed. Nonadherent Namalwa
cells were seeded at a density of 250000 cells per well in
4ml complete media in a 6-well plate. The LNA oligonu-
cleotides were used at a ﬁnal concentration of 10mM for
these cells. The total incubation time before cell lysis and
protein isolation was usually 6 or 10 days at 37 C.
Western blot analysis
Cells treated with oligonucleotides were washed in
PBS and then extracted in lysis buﬀer at 4 C for 1h.
Cell debris was removed by centrifugation at 14000g for
20min at 4 C. Protein concentrations were determined
using the Bio-Rad protein assay system (Bio-Rad Labora-
tories, Richmond, CA, USA). Aliquots of cell extracts,
containing 25–50mg of protein, were resolved by sodium
dodecylsulfate-polyacrylamide gel electrophoresis (SDS–
PAGE), and then transferred to Hybond ECL ﬁlter paper
(Amersham, Arlington Heights, IL, USA). After treatment
with the appropriate primary and secondary antibodies,
enhanced chemiluminescence was performed. The typical
margin error for a western blotting is at least 20–25%.
Immunoﬂuorescence
Cells were cultured and treated in LabTek chamber slides
(Nunc, Naperville, IL, USA), and treated gymnotically
with ﬂuoresceinated LNA oligonucleotides for 1, 3 and 6
days. For immunoﬂuorescence, cells were ﬁxed in 4%
paraformaldehyde in PBS (pH 7.4) for 15min, followed
by permeabilization with 0.1% Triton X-100 in PBS for 5
min. Cells were then incubated with 1% bovine serum
albumin (BSA) in PBS, pH 7.4, for 1 h at room tempera-
ture to block nonspeciﬁc binding of the antibodies,
followed for 1h at room temperature or overnight at
4 C with the anti-GW182 primary antibody (Abcam,
Cambridge, UK) diluted in the ratio 1:100 in PBS contain-
ing 1% BSA. After washing three times for 10min,
rhodamine-conjugated anti-mouse IgG (Santa Cruz
Biotechnology) was used as secondary antibody (1:100)
for detecting anti-GW182. The cells were then washed
and mounted using Vectashield mounting medium
(Vector Laboratories, Burlingame, CA, USA) prior to
microscopic analysis. Images were acquired using an
Olympus confocal microscope.
Isolation of RNA and RT–PCR
Total RNA was isolated from 518A2 cells using RNeasy
kit (Qiagen, Valencia, CA, USA) and quantitated by
ultraviolet absorption. RNA was reverse-transcribed
using reverse transcriptase-polymerase chain reaction
(RT–PCR) reactions based on the Super-ScriptTM One-
Step RT-PCR with Platinum Taq (Invitrogen). Bcl-2 was
ampliﬁed using 1mg of total RNA. The forward primer
was 50-GGTGCCACCTGTGGTCCACCTG-30. The
reverse primer was 50-CTTCACTTGTGGCCCAGATA
GG-30. The Bcl-2 amplicon was 459bp. The primers
50-GAGCTGCGTGTGGCTCCCGAGG-30, forward,
and 50-CGCAGGATGGCATGGGGGAGGGCATACC
CC-30, reverse, designed to amplify a 246-bp fragment of
b-actin were used to normalize for RNA concentration.
The RT–PCR products were resolved on 1% agarose gels
and visualized by ethidium bromide staining.
Quantitative RT–PCR. Total RNA from Namalwa
cells was extracted using the RNeasy kit (Qiagen,
The Netherlands) according to the manufacturer’s
instructions. The reverse transcription reaction was
carried out with random decamers, 0.5mg total RNA
and the M-MLV RT enzyme from (Applied Biosystems,
Carlsbad, CA, USA) according to protocol. First-strand
cDNA was subsequently diluted 10 times in nuclease-free
water before addition to the real-time PCR reaction
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genes were done using standard TaqMan assays
(Applied Biosystems). A 2-fold total RNA dilution series
from untreated Namalwa cells served as standard to
ensure a linear range (Ct versus relative copy number) of
the ampliﬁcation. The Applied Biosystems 7500 Real-
Time PCR instrument was used for ampliﬁcation.
In vivo studies in mice
These experiments were performed according to the prin-
ciples stated in the Danish law on animal experiments and
were approved by the Danish Animal Experiments Ins-
pectorate, Ministry of Justice, Denmark. Female NMRI
mice were treated intravenously with 0.9% saline or the
LNA oligonucleotides as described at doses of 5mg/kg/
day for three consecutive days, with each group comprising
ﬁve animals.Animals weresacriﬁced 24hafter thelast dose
and liver tissue was dissected and placed in RNA Later
stabilization reagent (Qiagen) until further analysis. Total
RNA was puriﬁed using the Qiagen spin columns accor-
ding to the manufacturer’s recommendations. Subsequen-
tly, target mRNA downregulation was quantitated by
quantitative reverse transcriptase-polymerase chain
reaction (qRT-PCR), as previously described.
RESULTS AND DISCUSSION
Gymnotic delivery produces gene silencing
Our initial studies employed 518A2 melanoma cells, a
line which is not chemo-sensitized by Bcl-2 silencing (7).
We embedded these cells in 3D collagen I gels, and
then treated them with 2.5–5mM SPC2996, a 16-mer
phosphorothioate oligonucleotide targeted to the codons
1–6 of the Bcl-2 mRNA. The oligonucleotide also contains
two LNA moieties at the 50 and one base upstream from
the 30 molecular termini (Table 1). These substitutions
increase the Tm of the mRNA–DNA duplex by  4–
6 C/base modiﬁcation, as well as virtually eliminating 30,
50-exonuclease digestion (8–11). After 6 days of continu-
ous culture, the cells were isolated by digestion of the
matrix by collagenase type I. After western blotting, sub-
stantial (>90%) silencing of Bcl-2 protein expression
versus control was observed (data not shown). To the
best of our knowledge, it has heretofore not been
possible to produce gene silencing in 3D gels when
particulates were employed.
Because the oligomers were delivered ‘naked’ (gymnos
in Greek), i.e. without conjugates or transfectants, we
have named this process gymnotic delivery. Subsequent
experiments were performed in plastic wells in the
absence of collagen I, and cells were plated at an initial
density such that they would become conﬂuent either
by 6 or 10 days. The optimal time for maximum Bcl-2
protein and mRNA silencing by gymnotic delivery in
518A2 cells was found to be 6–10 days (Figure 1A) and
3–5 days (Figure 1B), respectively. Gymnotic delivery of
numerous control oligonucleotides to 518A2 melanoma
cells did not produce any Bcl-2 protein silencing,
demonstrating the sequence speciﬁcity of the gymnotic
process (Figure 1C).
Gymnotic silencing is relatively slow compared with
lipofection-mediated silencing, where a standard 4h of
treatment with SPC2996 and 3 days incubation are
required for maximal mRNA and protein silencing.
(Also unlike lipofection, in which particulate matter
precipitates on the cells being transfected, a uniform,
deﬁned oligonucleotide concentration in the treatment
media is present during gymnosis). If, after 10 days of
treatment by SPC2996, cells were re-plated in complete
media at the original density and re-treated with
SPC2996, silencing was maintained for a further 10
days, until the experiment was terminated when cellular
conﬂuence was attained. This procedure was repeated
every 10 days for 17 consecutive times, and continuous
Bcl-2 protein silencing was achieved for SPC2996 for
>180 days in the absence of any carrier (Figure 1D).
However, when SPC2996 was removed from the media
after 10 days of gymnotic delivery to 518A2 cells, Bcl-2
protein expression returned to 50% of the levels
of baseline expression in 24h, and to 100% in  72h.
This was also the case after 180 days of continuous Bcl-
2 silencing, demonstrating that the silencing did not occur
at the level of cellular DNA (Figure 1D). However,
phosphodiester SPC2996 (i.e. SPC2996 with no
phosphorothioate linkages), with or without two LNA
modiﬁcations at the 30 and 50 molecular termini, did not
silence Bcl-2 protein expression in 518A2 cells after 10
days of gymnotic delivery (data not shown). This,
possibly, is due at least in part to its degradation by
endonuclease activity.
Gene silencing by gymnotic delivery
is a general phenomenon
Gymnotic delivery of SPC2996 leading to Bcl-2 protein
and mRNA silencing could be demonstrated in multiple
cell lines. Because of diﬀerent growth rates, the plating
densities of each cell line were determined so that conﬂu-
ence was achieved only at either 6 or 10 days. Eﬃcient
Table 1. List of the oligomers employed
Oligomer Target Sequence Length
(mer)
SPC2996 Bcl-2 16
SPC4088 Bcl-2 16
SPC4325 Bcl-2 16
SPC3302 ApoB 16
SPC3716 ApoB 12
SPC4007 ApoB 16
SPC5024 ApoB 12
SPC3046 Control 16
SPC3053 Control 16
SPC3088 Control 16
LNA-modiﬁed riboses are given in bold capital letters; whereas
small letters indicate deoxyriboses. s, Phosphorothioate; m, C5-
methylcytosine; FAM, 50-ﬂuorescein covalent conjugate.
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1000.36, 1036, 333.1 and 201.2 melanoma cells, PC3 and
LAPC-4 prostate cancer cells, Huh-7 hepatoma cells
(Figure 5A) and CaCo2 colon cancer cells, with essentially
the identical dose dependency as seen in 518A2 cells
(Supplementary Figure S1; and data not shown).
HT1080 ﬁbrosarcoma cells were very sensitive to
gymnotic silencing. The IC50 of Bcl-2 silencing by
SPC2996 was  100nM (Figure 2C, top). LNCaP cells,
which are notoriously diﬃcult to transfect with lipidic
particulates without extensive apoptosis, responded to
gymnotic delivery of SPC2996 with IC50 of Bcl-2 silencing
also  1mM (Figure 2C, bottom), and minimal if any
cytotoxicity. Treatment with multiple control oligomers
revealed no change in Bcl-2 expression in any cell line
(Figures 1C, 2B and C; and data not shown). In contrast,
A375 melanoma cells and SV40-transfected human
microvascular endothelial cells (HMEC-1) and primary
HUVEC cells were completely refractory with respect to
Bcl-2 silencing mediated by gymnotic delivery, although
not to lipofection (data not shown).
In Namalwa B cells, whose growth is anchorage
independent, and which are notoriously resistant to
lipofection, gymnotic delivery of the Bcl-2-targeted
oligomer SPC2996 led to an 80% decrease in Bcl-2
mRNA expression after 6 days, while no silencing by a
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Figure 1. Gymnotic delivery leads to long-term Bcl-2 silencing in 518 A2 melanoma cells. (A) Time course of Bcl-2 protein silencing in 518A2
melanoma cells after gymnotic delivery of SPC2996. Maximum protein silencing was observed after  6–7 days for SPC2996. C, untreated control.
(B) RT–PCR evaluation of Bcl-2 mRNA levels in 518A2 melanoma cells demonstrating silencing after 6 days in the gymnotic delivery experiment in
Figure 1A. C, untreated control; C*, single primer only. (C) Western blots in 518A2 melanoma cells demonstrating silencing of Bcl-2 protein by
gymnotic delivery (6 days) of the sequence-speciﬁc anti-Bcl-2 phosphorothioate LNA gap-mer SPC2996. Three control oligomers with scrambled
sequence, of which one (SPC3053) has identical chemistry to SPC2996, were inactive. (D) Iterative re-addition of SPC2996 (2.5mM) produces long-
term silencing. 518A2 melanoma cells were treated with SPC2996 at a plating density to ensure that the cells were conﬂuent only by Day 10, and then
re-plated at that density in the presence of 2.5mM oligomer. This process was repeated after 10 additional days. Seventeen repetitions were
performed. Bcl-2 protein silencing was continuously maintained after 180 consecutive days. However, if the oligomer was removed after 180
days, baseline levels of Bcl-2 protein were restored after 3 days.
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gymnotic delivery was also eﬃciently accomplished
in multiple cell lines by both anti-survivin and anti-HIF-
1a oligomers (518A2 and 1000.36 melanoma cells; data
not shown), both of which are LNA phosphorothioate
oligonucleotides with equal length and design as
SPC2996. No silencing was observed with a scrambled
version of the anti-HIF-1a oligomer. Dose dependencies
were similar to what was observed for SPC2996.
Target-speciﬁc eﬀects of gymnotic delivery
It has been previously demonstrated (12,13) that the
lipids (e.g. lipofectin and oligofectamine) employed in
oligonucleotide transfection can, in some cell lines,
induce marked gene changes that may result in early
apoptosis. This is particularly true in 518A2 melanoma
cells, where lipofection of SPC2996 eﬀectively silences
Bcl-2, but also simultaneously causes PARP-1 cleavage
and pro-caspase-3 cleavage to caspase-3 (14). We
examined the silencing of other Bcl-2 and apoptosis-
related targets after 6 days of Bcl-2 silencing by
SPC2996 in 518A2 melanoma cells. There were no
changes in the levels of expression of Bcl-xL, p21,
PKC-a, Mcl-1 or tubulin proteins. PARP-1 and pro-
caspase 3 were not cleaved (Figure 3). Levels of survivin
protein ﬂuctuated unpredictably from baseline to elevated,
depending on the particular experiment, and are thus
considered to be epiphenomenal.
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Figure 2. Gymnotic delivery and silencing is observed in many cell lines. (A) Silencing of Bcl-2 protein expression in the 591.8, 1036 and 1000.36
melanoma cell lines by 2.5 and 5mM SPC2996. Cells were treated for 10 days by gymnotic delivery before western blotting was performed. C,
untreated control. (B) Separate experiments were performed to examine silencing of Bcl-2 protein expression in 591.8, 1036 and 1000.36 melanoma
cell lines by 5mM SPC2996 and the scrambled control oligomer SPC3046. Cells were treated for 6 days by gymnotic delivery before western blotting
was performed. (C) Top: gymnotic delivery (10 days) and diﬀerential silencing of Bcl-2 protein expression in HT1080 ﬁbrosarcoma cells by SPC2996.
To the right, separate experiments were performed to examine gymnotic silencing of Bcl-2 (6 days) by SPC2996 and the scrambled control oligomer
SPC3046; bottom: gymnotic delivery and silencing (10 days) of Bcl-2 protein expression in LNCaP cells, which can be accomplished with minimum
toxicity, as compared with lipofection. (D) In vitro eﬀects of the gymnotic delivery of SPC2996 on the expression of the Bcl-2 mRNA in Namalwa
Burkitt’s lymphoma cells. qPCR analysis of Bcl-2 mRNA expression was performed after exposure to SPC2996 or SPC3088, the control oligomer
(10mM, ﬁnal concentrations) for the indicated times. qPCR values represent the mean±SD (n=3).
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518A2 melanoma cells was determined by ﬂow cytometry
after 6 days of gymnotic delivery, and compared with
lipofection. After 6 days, a single Gaussian-shaped peak
in the histogram of ﬂuorescence channel number versus
number of cell sorted was observed (Supplementary
Figure S2), in sharp contrast with the three peaks seen
after lipotransfection, where the peak with the highest
channel number corresponded to the bright nuclear
staining customarily seen by ﬂuorescence microscopy. In
contrast, very little nuclear ﬂuorescence, as opposed to
cytoplasmic ﬂuorescence, was observed at any time after
gymnotic delivery of 50-FAM-SPC2996, a molecule
that produces >95% Bcl-2 silencing in 518A2 cells
(Figure 4). This observation is in sharp distinction to the
widely held belief that intense nuclear staining is required
2.5 mM
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SPC4007
16mer
GW182 antibody FAM-LNA Merged A
B
2.5 mM
SPC5024
12mer
2.5 mM
SPC4007
16mer
GW182 antibody FAM-LNA Merged
Figure 4. Co-localization of LNA oligonucleotides with gw182, a GW/P body marker. Confocal microscopic imaging of Huh-7 cells after gymnotic
delivery of either a 12-mer (SPC5024) or a 16-mer (SPC4007) anti-ApoB 50-FAM-30,5 0-end-capped LNA phosphorothioate gap-mer. After 1 day (A)
or 3 days (B) of delivery, cells were ﬁxed and stained with an anti-gw182 primary antibody and visualized with a rhodamine-conjugated secondary
antibody. After image merging, the oligomers were observed co-localizing with the GW/P body marker. The 12-mer accumulated more rapidly than
the 16-mer after 1 day, but after 3 days of gymnotic delivery, the accumulation in the GW/P bodies are approximately equivalent.
C
Bcl-XL
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Tubulin
Bcl-2 Mcl-1
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Caspase 3
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Figure 3. Oﬀ-target eﬀects after gymnotic delivery. Oﬀ-target eﬀects
of the gymnotic silencing of Bcl-2 by 2.5mM SPC2996 in 518A2
melanoma cells (6 days). As seen in these western blots, no changes in
the expression of Bcl-xL, tubulin, Mcl-1, PKC-a or survivin proteins were
observed. Furthermore, unlike after lipofection of SC2996, Bcl-2 silencing
was not associated with either PARP-1 or pro-caspase-3 cleavage.
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nuclear (lipofection) and cytoplasmic (gymnotic delivery)
ﬂuorescence of this molecule after ﬂuorescence photo-
bleaching revealed rapid recovery of ﬂuorescence in the
nucleus, but almost no recovery in the cytoplasm,
indicating a strong interaction of the oligomer with
intracytoplasmic components (data not shown).
Gymnotically delivered oligonucleotides apparently
localize to P-bodies
An anti-Apo-B 16-mer (50-FAM-SPC4007) (15) or
50-FAM-SPC5024, a 12-mer truncated variant, was
gymnotically delivered to Huh-7 hepatocellular carcinoma
cells for 1 and 3 days each (Figure 4A and B, respectively).
The cells were then labeled with a GW/P-body-speciﬁc
antibody targeted to the GW182 protein; it thus detects
the cytoplasmic site of the RNA silencing machinery
(16,17). The apparent co-localization of the 12-mer
oligomer with the GW182 protein was observed after 1
day of gymnotic delivery, but only after 3 days for the
16-mer. In addition, the more rapid kinetics induction of
GW/P body formation by the 12-mer versus the 16-mer
after gymnotic delivery correlated with increased ApoB
mRNA silencing in vitro (Figure 5A).
Gymnotic in vitro silencing correlates with in vivo
silencing
Given the former in vitro requirement for delivery
adjuvants, it has always been deemed paradoxical that
in vivo silencing by oligonucleotides proceeded in the
absence of transfection reagents. We treated female
NMRI mice intravenously with SPC3302 (16-mer anti-
ApoB) or SPC3716 (12-mer anti-ApoB) at doses of
5mg/kg/day 3 days; hepatic mRNA was isolated and
subjected to qRT-PCR (Figure 5B). The decline in
ApoB mRNA expression was 2.5-fold greater for the
12-mer versus the 16-mer, although the rate of plasma
clearance of the two oligomers was virtually identical
(10). In contrast, when the anti-ApoB 16-mer or the
12-mer was lipofected into Huh-7 cells in vitro, the
extent of dose-dependent mRNA silencing favored the
16-mer (Figure 5C). Almost identical in vitro and in vivo
results were found with an anti-HIF-1a oligomer with the
same gap-mer design; the in vivo potency was predicted by
AB
C
Figure 5. In vitro gymnotic delivery and silencing correlates with in vivo gene silencing. (A) Increased potency of an anti-ApoB 30,50-end-capped
LNA–phosphorothioate 12-mer gap-mer (SPC3716) versus a 16-mer (SPC3302) after 6 days of in vitro gymnotic delivery to Huh-7 cells. ApoB
mRNA silencing data are presented as the average±SD (n=3;*P<0.0001 by Student’s t-test assuming unequal variances). (B) In vivo silencing of
intra-hepatic ApoB mRNA expression in female NMRI mice after intravenous delivery (5mg/kg i.v., Days 0, 1 and 2), demonstrating the increase in
potency for the 12-mer versus the 16-mer. Data are presented as the average±SD (n=3; **P<0.02 by Student’s t-test assuming unequal
variances). (C) In vitro lipofection (Lipofectamine 2000) of the 12-mer and 16-mer anti-ApoB oligomers into Huh-7 human hepatoma cells,
demonstrating the increased potency of the latter compared with its 12-mer counterpart. In contrast to the in vitro gymnotic delivery data, these
results are inversely correlated with the in vivo data. Data are presented as the average±SD (n=3).
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mediated, silencing data.
In retrospect, what we now call gymnotic silencing has
been previously observed with thiophosphoramidate
oligomers (18), but to our knowledge it has never been
recognized as a general delivery principle. Moreover,
LNA gap-mers are not the only chemistry active in
gymnosis, 20-deoxy, 20-ﬂuoro, b-D-arabinonucleic acid
(FANA) phosphorothioate gap-mers (19) are also active.
Less expensive, unmodiﬁed phosphorothioate oligonu-
cleotides are, in general, not active, with the exception of
G3139 [a.k.a genasense, oblimersen (20)], an 18-mer
targeted to the same region of the Bcl-2 mRNA as
SPC2996, although with relatively decreased potency
versus SPC2996. Some 20-O-methyl modiﬁed
phosphorothioate oligomers show activity, but rules gov-
erning gymnosis for this class of molecule have not yet
emerged. Our preliminary results suggest that uncharged
oligonucleotides (e.g. peptide and morpholino nucleic
acids) are not active.
In toto, our data demonstrate that in vitro silencing by
the gymnotic delivery of LNA antisense oligodeoxynu-
cleotides, which we have demonstrated in multiple cell
lines, with several targets, and in 3D collagen I gels,
can be highly eﬃcient and produce far less toxicity
than standard lipofection techniques. Further, the
long-accepted dogma that elevated nuclear levels of
oligonucleotide is a requirement for silencing has been
shown to be incorrect. In addition, as the experiments
comparing the 16-mer and 12-mer variants of anti-ApoB
oligomers demonstrated, in vitro gymnotic silencing may
be linked with and be a better predictor of in vivo silencing
eﬃcacy than lipofection. Because of the elimination of
toxic lipids and all other transfection reagents, we thus
believe that the expansion of this simple, accessible
method will prove to be paradigm shifting in the area of
antisense oligonucleotide research.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
Funding for open access charge: NCI R01 CA108415 and
Santaris to CAS.
Conﬂict of interest statement. C.A.S. received research
funding from and is a scientiﬁc advisor to Santaris
(Copenhagen, DK). J.L., B.R.H., H.O., T.K., J.W.,
M.H. and A.H. are employees of Santaris.
REFERENCES
1. Akhtar,S., Basu,S., Wickstrom,W. and Juliano,R. (1991)
Interactions of antisense DNA oligonucleotide analogs with
phospholipid membranes (liposomes). Nucleic Acids Res., 19,
5551–5559.
2. Walder,R. and Walder,J. (1988) Role of RNAse H in
hybrid-arrested translation by antisense oligonucleotides.
Proc. Natl Acad. Sci. USA, 85, 5011–5015.
3. Marcusson,E., Bhat,B., Manoharan,M., Bennett,F. and Dean,N.
(1998) Phosphorothioate oligonucleotides dissociate from cationic
lipids before entering the nucleus. Nucleic Acids Res., 26,
2016–2023.
4. Fisher,T., Terhorst,T., Cao,X. and Wagner,R. (1993) Intracellular
disposition and metabolism of ﬂuorescently-labeled unmodiﬁed and
modiﬁed oligonucleotides microinjected into mammalian cells.
Nucleic Acids Res., 21, 3857–3865.
5. Moulds,C., Lewis,J., Froehler,B., Grant,D., Huang,T., Milligan,J.,
Matteucci,M. and Wagner,R. (1995) Site and mechanism of
antisense inhibition of C-5 propyne oligonucleotides. Biochemistry,
34, 5044–5053.
6. Flanagan,W. and Wagner,R. (1998) The development of C-5
propyne oligonucleotides as inhibitors of gene function. In Stein,C.
and Krieg,A. (eds), Applied Antisense Oligonucleotide Technology.
Wiley-Liss, New York, pp. 175–192.
7. Benimetskaya,L., Lai,J., Wu,S., Hua,E., Khvorova,A., Miller,P.
and Stein,C.A. (2004) Relative Bcl-2 independence of drug induced
cytotoxicity and resistance in 518A2 melanoma cells. Clin. Cancer
Res., 10, 8371–8379.
8. Koshkin,A., Singh,S., Nielsen,P., Rajwanshi,R., Meldgaard,M.,
Olsen,C. and Wengel,J. (1998) LNA (locked nucleic acids):
synthesis of the adenine, cytosine, guanine, 5-methylcytosine,
thymine and uracil bicyclonucleoside monomers, oligomerisation,
and unprecedented nucleic acid recognition. Tetrahedron, 54,
3607–3630.
9. Singh,S., Nielsen,P., Koshkin,A. and Wengel,J. (1998) LNA (locked
nucleic acids): synthesis and high-aﬃnity nucleic acid recognition.
Chem. Commun., 455–456.
10. Singh,S. and Wengel,J. (1998) Universality of LNA-medicated
high-aﬃnity nucleic acid recognition. Chem. Commun., 1247–1248.
11. Koch,T., Rosenbohm,C., Hansen,H.F., Hansen,B., Straarup,E.M.
and Kauppinen,S. (2008) Locked nucleic acid: properties and
therapeutic aspects. In Kurreck,J. (ed.), Therapeutic
Oligonucleotides. RSC Publishing, Cambridge, pp. 103–134.
12. Akhtar,S. and Benter,I. (2007) Toxicogenomics of non-viral drug
delivery systems for RNAi: potential impact on siRNA-mediated
gene silencing activity and speciﬁcity. Adv. Drug Deliv. Rev., 59,
164–182.
13. Omidi,Y., Hollins,A., Benboubetra,M., Drayton,R. and Akhtar,S.
(2003) Toxicogenomics of non-viral vectors for gene therapy:
a microarray study of lipofectin- and oligofectamine-induced
gene expression changes in human epithelial cells. J. Drug. Target.,
11, 311–323.
14. Lai,J.C., Benimetskaya,L., Khvorova,A., Wu,S., Hua,E., Miller,P.
and Stein,C.A. (2005) Phosphorothioate oligodeoxynucleotides and
G3139 induce apoptosis in 518A2 melanoma cells. Mol. Cancer
Ther., 4, 305–315.
15. Koch,T. and Oerum,H. (2008) Locked nucleic acid. In Crooke,S.
(ed.), Antisense Drug Technology, 2nd edn. CRC Press, Boca Raton,
FL, pp. 519–562.
16. Jakymiw,A., Lian,S., Eystathioy,T., Li,S., Satoh,M., Hamel,J.C.,
Fritzler,M.J. and Chan,E.K. (2005) Disruption of GW bodies
impairs mammalian RNA interference. Nat. Cell Biol., 7,
1267–1274.
17. Sen,G.L. and Blau,H.M. (2005) Argonaute 2/RISC resides
in sites of mammalian mRNA decay known as cytoplasmic bodies.
Nat. Cell Biol., 7, 633–636.
18. Dikmen,Z.G., Wright,W.E., Shay,J.W. and Gryaznov,S.M. (2008)
Telomerase targeted oligonucleotide thio-phosphoramidates
in T24-luc bladder cancer cells. J. Cell. Biochem., 104, 444–452.
19. Ferrari,N., Bergeron,D., Tedeschi,A., Mangos,M., Paquet,L.,
Renzi,P. and Damha,M. (2008) Characterization of antisense
oligonucleotides comprising 20-deoxy, 20-ﬂuoro-beta-D-
arabinonucleic acid (FANA); speciﬁcity, potency and duration
of activity. Ann. NY Acad. Sci., 1082, 91–102.
20. Stein,C., Wu,S., Voskresenskiy,A., Zhou,J., Shin,J., Miller,P. and
Benimetskaya,L. (2009) G3139, an anti-Bcl-2 antisense oligomer
that binds heparin-binding growth factors and collagen I, alters
in vitro endothelial cell growth and tubular morphogenesis.
Clin. Cancer Res., 15, 2797–2807.
e3 Nucleic AcidsResearch, 2010,Vol. 38,No. 1 PAGE 8 OF 8